APA (7th ed.) Citation

PA, H., IW, F., N, W., JA, B., GP, C., PB, C., . . . MR, P. (2019). Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study. American journal of hematology, 94(4), E90. https://doi.org/10.1002/ajh.25387

Chicago Style (17th ed.) Citation

PA, Hamlin, et al. "Efficacy and Safety of the Dual SYK/JAK Inhibitor Cerdulatinib in Patients with Relapsed or Refractory B-cell Malignancies: Results of a Phase I Study." American Journal of Hematology 94, no. 4 (2019): E90. https://doi.org/10.1002/ajh.25387.

MLA (9th ed.) Citation

PA, Hamlin, et al. "Efficacy and Safety of the Dual SYK/JAK Inhibitor Cerdulatinib in Patients with Relapsed or Refractory B-cell Malignancies: Results of a Phase I Study." American Journal of Hematology, vol. 94, no. 4, 2019, p. E90, https://doi.org/10.1002/ajh.25387.